Embryonic template-based generation and purification of pluripotent stem cell-derived cardiomyocytes for heart repair

Journal of Cardiovascular Translational Research

Volumn 5, Issue 5, 2012, Pages 566-580

  Dierickx, Pieterjan ^a,b,c   Doevendans, Pieter A ^a,d   Geijsen, Niels ^b   Van Laake, Linda W ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HUBRECHT INSTITUTE   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Cardiomyocytes; Directed differentiation; Embryonic stem cells (ESCs); Heart repair; Induced pluripotent stem cells (iPSCs); Myocardial infarction (MI); Tissue engineering

Indexed keywords

ASCORBIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROSTACYCLIN; WNT3A PROTEIN; BIOLOGICAL MARKER;

ADULT STEM CELL; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CELL SURFACE; COCULTURE; DRUG MECHANISM; EMBRYO PATTERN FORMATION; EMBRYOID BODY; EMBRYONIC STEM CELL; ENRICHMENT CULTURE; GASTRULATION; HEART DEVELOPMENT; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; MESODERM; MONOLAYER CULTURE; MUSCLE REGENERATION; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REPAIR; ANIMAL; CELL SEPARATION; CELL SURVIVAL; CONVALESCENCE; CULTURE TECHNIQUE; GENE EXPRESSION REGULATION; GENOTYPE; HEART CONTRACTION; HEART MUSCLE; METABOLISM; METHODOLOGY; MORPHOGENESIS; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; REGENERATION; REGENERATIVE MEDICINE; REVIEW; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINEAGE; CELL SEPARATION; CELL SURVIVAL; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENOTYPE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MORPHOGENESIS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; PHENOTYPE; RECOVERY OF FUNCTION; REGENERATION; REGENERATIVE MEDICINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84874158721     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9391-6     Document Type: Article

References (190)

1. Eefting, F.; et al. (2004). Role of apoptosis in reperfusion injury. Cardiovascular Research, 61(3), 414-426.
2. Laflamme, M. A.; et al. (2005). Formation of human myocardium in the rat heart from human embryonic stem cells. The American Journal of Pathology, 167(3), 663-671.
3. Roger, V. L.; et al. (2011). Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation, 123(4), e18-e209.
4. Beltrami, A. P.; et al. (2001). Evidence that human cardiac myocytes divide after myocardial infarction. The New England Journal of Medicine, 344(23), 1750-1757.
5. Urbanek, K.; et al. (2005). Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proceedings of the National Academy of Sciences of the United States of America, 102(24), 8692-8697.
6. Anversa, P.; Leri, A.; Kajstura, J. (2006). Cardiac regeneration. Journal of the American College of Cardiology, 47(9), 1769-1776.
7. Beltrami, A. P.; et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114(6), 763-776.
8. Bergmann, O.; et al. (2009). Evidence for cardiomyocyte renewal in humans. Science, 324(5923), 98-102.
9. Raikwar, S. P.; Mueller, T.; Zavazava, N. (2006). Strategies for developing therapeutic application of human embryonic stem cells. Physiology (Bethesda), 21, 19-28.
10. Goumans, M. J.; et al. (2007). TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Research, 1(2), 138-149.
11. Bollini, S.; Smart, N.; Riley, P. R. (2011). Resident cardiac progenitor cells: at the heart of regeneration. Journal of Molecular and Cellular Cardiology, 50(2), 296-303.
12. Steinhauser, M. L.; Lee, R. T. (2011). Regeneration of the heart. EMBO Molecular Medicine, 3(12), 701-712.
13. Vidarsson, H.; Hyllner, J.; Sartipy, P. (2010). Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Reviews, 6(1), 108-120.
14. Kattman, S. J.; et al. (2011). Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell, 8(2), 228-240.
15. Burridge, P. W.; et al. (2011). A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One, 6(4), e18293.
16. Willems, E.; et al. (2011). A chemical biology approach to myocardial regeneration. Journal of Cardiovascular Translational Research, 4(3), 340-350.
17. Laflamme, M. A.; et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25(9), 1015-1024.
18. Uosaki, H.; et al. (2011). Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One, 6(8), e23657.
19. Elliott, D. A.; et al. (2011). NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nature Methods, 8, 1037-1040.
20. Hudson, J.; et al. (2012). Primitive cardiac cells from human embryonic stem cells. Stem Cells Development, 21(9), 1513-1523.
21. Passier, R.; van Laake, L. W.; Mummery, C. L. (2008). Stem-cell-based therapy and lessons from the heart. Nature, 453(7193), 322-329.
22. van Laake, L. W.; et al. (2008). Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents. Circulation Research, 102(9), 1008-1010.
23. Kattman, S. J.; et al. (2011). Stem cells and their derivatives: a renaissance in cardiovascular translational research. Journal of Cardiovascular Translational Research, 4(1), 66-72.
24. Davis, R. P.; et al. (2011). Pluripotent stem cell models of cardiac disease and their implication for drug discovery and development. Trends in Molecular Medicine, 17(9), 475-484.
25. Evans, M. J.; Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature, 292(5819), 154-156.
26. Martin, G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the National Academy of Sciences of the United States of America, 78(12), 7634-7638.
27. Thomson, J. A.; et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145-1147.
28. Mummery, C.; et al. (2003). Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation, 107(21), 2733-2740.
29. Kehat, I.; et al. (2001). Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. The Journal of Clinical Investigation, 108(3), 407-414.
30. Gai, H.; et al. (2009). Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biology International, 33(11), 1184-1193.
31. Xu, C.; et al. (2002). Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circulation Research, 91(6), 501-508.
32. Takahashi, K.; Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.
33. Takahashi, K.; et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.
34. Kim, K.; et al. (2011). Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nature Biotechnology, 29(12), 1117-1119.
35. Cherry, A. B.; Daley, G. Q. (2012). Reprogramming cellular identity for regenerative medicine. Cell, 148(6), 1110-1122.
36. Schenke-Layland, K.; et al. (2008). Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells, 26(6), 1537-1546.
37. Narazaki, G.; et al. (2008). Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation, 118(5), 498-506.
38. Zhang, J.; et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104(4), e30-e41.
39. Nelson, T. J.; et al. (2009). Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation, 120(5), 408-416.
40. Zhao, T.; et al. (2011). Immunogenicity of induced pluripotent stem cells. Nature, 474(7350), 212-215.
41. Okita, K.; Nagata, N.; Yamanaka, S. (2011). Immunogenicity of induced pluripotent stem cells. Circulation Research, 109(7), 720-721.
42. Moriguchi, H.; Chung, R. T.; Sato, C. (2010). Tumorigenicity of human induced pluripotent stem cells depends on the balance of gene expression between p21 and p53. Hepatology, 51(3), 1088-1089.
43. Ghosh, Z.; et al. (2011). Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Research, 71(14), 5030-5039.
44. Lin, S. L.; et al. (2010). MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Research, 70(22), 9473-9482.
45. Okita, K.; Ichisaka, T.; Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313-317.
46. Okita, K.; et al. (2008). Generation of mouse induced pluripotent stem cells without viral vectors. Science, 322(5903), 949-953.
47. Stadtfeld, M.; et al. (2008). Induced pluripotent stem cells generated without viral integration. Science, 322(5903), 945-949.
48. Yu, J.; et al. (2009). Human induced pluripotent stem cells free of vector and transgene sequences. Science, 324(5928), 797-801.
49. Jia, F.; et al. (2010). A nonviral minicircle vector for deriving human iPS cells. Nature Methods, 7(3), 197-199.
50. Narsinh, K. H.; et al. (2011). Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nature Protocols, 6(1), 78-88.
51. Warren, L.; et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7(5), 618-630.
52. Anokye-Danso, F.; et al. (2011). Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell, 8(4), 376-388.
53. Woltjen, K.; et al. (2009). piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 458(7239), 766-770.
54. Hu, K.; et al. (2011). Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood, 117(14), e109-e119.
55. Seki, T.; Yuasa, S.; Fukuda, K. (2012). Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nature Protocols, 7(4), 718-728.
56. Ban, H.; et al. (2011). Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proceedings of the National Academy of Sciences of the United States of America, 108(34), 14234-14239.
57. Fusaki, N.; et al. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 85(8), 348-362.
58. Rao, M. S.; Malik, N. (2012). Assessing iPSC reprogramming methods for their suitability in translational medicine. Journal of Cell Biochemistry. doi: 10.1002/jcb.24183.
59. Lai, M. I.; et al. (2011). Advancements in reprogramming strategies for the generation of induced pluripotent stem cells. Journal of Assisted Reproduction and Genetics, 28(4), 291-301.
60. Okita, K.; Yamanaka, S. (2011). Induced pluripotent stem cells: opportunities and challenges. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 366(1575), 2198-2207.
61. Stadtfeld, M.; Hochedlinger, K. (2010). Induced pluripotency: history, mechanisms, and applications. Genes & Development, 24(20), 2239-2263.
62. Lawson, K. A.; Meneses, J. J.; Pedersen, R. A. (1991). Clonal analysis of epiblast fate during germ layer formation in the mouse embryo. Development, 113(3), 891-911.
63. Willems, E.; Bushway, P. J.; Mercola, M. (2009). Natural and synthetic regulators of embryonic stem cell cardiogenesis. Pediatric Cardiology, 30(5), 635-642.
64. Mercola, M.; Ruiz-Lozano, P.; Schneider, M. D. (2011). Cardiac muscle regeneration: lessons from development. Genes & Development, 25(4), 299-309.
65. Burridge, P. W.; et al. (2012). Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell, 10(1), 16-28.
66. Bondue, A.; et al. (2008). Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. Cell Stem Cell, 3(1), 69-84.
67. Bondue, A.; Blanpain, C. (2010). Mesp1: a key regulator of cardiovascular lineage commitment. Circulation Research, 107(12), 1414-1427.
68. David, R.; et al. (2008). MesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling. Nature Cell Biology, 10(3), 338-345.
69. Lindsley, R. C.; et al. (2008). Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. Cell Stem Cell, 3(1), 55-68.
70. Hiroi, Y.; et al. (2001). Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nature Genetics, 28(3), 276-280.
71. Plageman, T. F.; Jr.; Yutzey, K. E. (2004). Differential expression and function of Tbx5 and Tbx20 in cardiac development. Journal of Biological Chemistry, 279(18), 19026-19034.
72. Riley, P.; Anson-Cartwright, L.; Cross, J. C. (1998). The Hand1 bHLH transcription factor is essential for placentation and cardiac morphogenesis. Nature Genetics, 18(3), 271-275.
73. Buckingham, M.; Meilhac, S.; Zaffran, S. (2005). Building the mammalian heart from two sources of myocardial cells. Nature Reviews Genetics, 6(11), 826-835.
74. Klaus, A.; et al. (2007). Distinct roles of Wnt/beta-catenin and Bmp signaling during early cardiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 104(47), 18531-18536.
75. Cai, C. L.; et al. (2003). Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. Developmental Cell, 5(6), 877-889.
76. Ilagan, R.; et al. (2006). Fgf8 is required for anterior heart field development. Development, 133(12), 2435-2445.
77. Kelly, R. G.; Brown, N. A.; Buckingham, M. E. (2001). The arterial pole of the mouse heart forms from Fgf10-expressing cells in pharyngeal mesoderm. Developmental Cell, 1(3), 435-440.
78. Xu, H.; et al. (2004). Tbx1 has a dual role in the morphogenesis of the cardiac outflow tract. Development, 131(13), 3217-3227.
79. Meilhac, S. M.; et al. (2004). The clonal origin of myocardial cells in different regions of the embryonic mouse heart. Developmental Cell, 6(5), 685-698.
80. Waldo, K. L.; et al. (2001). Conotruncal myocardium arises from a secondary heart field. Development, 128(16), 3179-3188.
81. Mjaatvedt, C. H.; et al. (2001). The outflow tract of the heart is recruited from a novel heart-forming field. Developmental Biology, 238(1), 97-109.
82. Dyer, L. A.; Kirby, M. L. (2009). Sonic hedgehog maintains proliferation in secondary heart field progenitors and is required for normal arterial pole formation. Developmental Biology, 330(2), 305-317.
83. Goddeeris, M. M.; et al. (2008). Intracardiac septation requires hedgehog-dependent cellular contributions from outside the heart. Development, 135(10), 1887-1895.
84. Kwon, C.; et al. (2007). Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. Proceedings of the National Academy of Sciences of the United States of America, 104(26), 10894-10899.
85. Ai, D.; et al. (2007). Canonical Wnt signaling functions in second heart field to promote right ventricular growth. Proceedings of the National Academy of Sciences of the United States of America, 104(22), 9319-9324.
86. Cohen, E. D.; et al. (2007). Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. The Journal of Clinical Investigation, 117(7), 1794-1804.
87. Grego-Bessa, J.; et al. (2007). Notch signaling is essential for ventricular chamber development. Developmental Cell, 12(3), 415-429.
88. Watanabe, Y.; et al. (2006). Activation of Notch1 signaling in cardiogenic mesoderm induces abnormal heart morphogenesis in mouse. Development, 133(9), 1625-1634.
89. Lavine, K. J.; et al. (2005). Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Developmental Cell, 8(1), 85-95.
90. Brade, T.; et al. (2011). Retinoic acid stimulates myocardial expansion by induction of hepatic erythropoietin which activates epicardial Igf2. Development, 138(1), 139-148.
91. Phillips, H. M.; et al. (2005). Vangl2 acts via RhoA signaling to regulate polarized cell movements during development of the proximal outflow tract. Circulation Research, 96(3), 292-299.
92. Zhou, W.; et al. (2007). Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/CREB family-mediated transcriptional activation of TGFbeta2. Nature Genetics, 39(10), 1225-1234.
93. Shi, Y.; et al. (2000). BMP signaling is required for heart formation in vertebrates. Developmental Biology, 224(2), 226-237.
94. Walters, M. J.; Wayman, G. A.; Christian, J. L. (2001). Bone morphogenetic protein function is required for terminal differentiation of the heart but not for early expression of cardiac marker genes. Mechanisms of Development, 100(2), 263-273.
95. Zhao, Y.; Samal, E.; Srivastava, D. (2005). Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature, 436(7048), 214-220.
96. Chen, J. F.; et al. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nature Genetics, 38(2), 228-233.
97. Evans-Anderson, H. J.; Alfieri, C. M.; Yutzey, K. E. (2008). Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors. Circulation Research, 102(6), 686-694.
98. Synnergren, J.; et al. (2008). Molecular signature of cardiomyocyte clusters derived from human embryonic stem cells. Stem Cells, 26(7), 1831-1840.
99. Cao, F.; et al. (2008). Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS One, 3(10), e3474.
100. Xu, X. Q.; et al. (2009). Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells, 27(9), 2163-2174.
101. Passier, R.; et al. (2005). Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells, 23(6), 772-780.
102. Freund, C.; et al. (2008). Insulin redirects differentiation from cardiogenic mesoderm and endoderm to neuroectoderm in differentiating human embryonic stem cells. Stem Cells, 26(3), 724-733.
103. Graichen, R.; et al. (2008). Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation, 76(4), 357-370.
104. Gaur, M.; et al. (2010). Timed inhibition of p38MAPK directs accelerated differentiation of human embryonic stem cells into cardiomyocytes. Cytotherapy, 12(6), 807-817.
105. Xu, X. Q.; et al. (2008). Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation, 76(9), 958-970.
106. Fujiwara, M.; et al. (2011). Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One, 6(2), e16734.
107. Itskovitz-Eldor, J.; et al. (2000). Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. Molecular Medicine, 6(2), 88-95.
108. Desbaillets, I.; et al. (2000). Embryoid bodies: an in vitro model of mouse embryogenesis. Experimental Physiology, 85(6), 645-651.
109. Doetschman, T. C.; et al. (1985). The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. Journal of Embryology and Experimental Morphology, 87, 27-45.
110. Tran, T. H.; et al. (2009). Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. Stem Cells, 27(8), 1869-1878.
111. He, J. Q.; et al. (2003). Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circulation Research, 93(1), 32-39.
112. Bu, L.; et al. (2009). Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature, 460(7251), 113-117.
113. Cao, N.; et al. (2012). Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells promoting the proliferation of cardiac progenitor cells. Cell Research, 22(1), 219-36.
114. McDevitt, T. C.; Laflamme, M. A.; Murry, C. E. (2005). Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway. Journal of Molecular and Cellular Cardiology, 39(6), 865-873.
115. Tseng, A. S.; Engel, F. B.; Keating, M. T. (2006). The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chemical Biology, 13(9), 957-963.
116. Ng, E. S.; et al. (2005). Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood, 106(5), 1601-1603.
117. Rajala, K.; Pekkanen-Mattila, M.; Aalto-Setala, K. (2011). Cardiac differentiation of pluripotent stem cells. Stem Cells International, 2011, 383709.
118. Sugi, Y.; Lough, J. (1995). Activin-A and FGF-2 mimic the inductive effects of anterior endoderm on terminal cardiac myogenesis in vitro. Developmental Biology, 168(2), 567-574.
119. Shiba, Y.; Hauch, K. D.; Laflamme, M. A. (2009). Cardiac applications for human pluripotent stem cells. Current Pharmaceutical Design, 15(24), 2791-2806.
120. Paige, S. L.; et al. (2010). Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS One, 5(6), e11134.
121. Filipczyk, A. A.; et al. (2007). Regulation of cardiomyocyte differentiation of embryonic stem cells by extracellular signalling. Cellular and Molecular Life Sciences, 64(6), 704-718.
122. Yang, L.; et al. (2008). Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature, 453(7194), 524-528.
123. Willems, E.; Mercola, M. (2011). What your heart doth know. Cell Stem Cell, 8(2), 124-126.
124. David, R.; et al. (2009). Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. Cardiovascular Research, 84(2), 263-272.
125. Dambrot, C.; et al. (2011). Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochemical Journal, 434(1), 25-35.
126. Nussbaum, J.; et al. (2007). Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. The FASEB Journal, 21(7), 1345-1357.
127. Behfar, A.; et al. (2007). Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. The Journal of Experimental Medicine, 204(2), 405-420.
128. Braam, S. R.; Passier, R.; Mummery, C. L. (2009). Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends in Pharmacological Sciences, 30(10), 536-545.
129. Kolossov, E.; et al. (2006). Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. The Journal of Experimental Medicine, 203(10), 2315-2327.
130. Miura, K.; et al. (2009). Variation in the safety of induced pluripotent stem cell lines. Nature Biotechnology, 27(8), 743-745.
131. Christoforou, N.; et al. (2010). Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts. PLoS One, 5(7), e11536.
132. Adler, E. D.; et al. (2010). The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction. The FASEB Journal, 24(4), 1073-1081.
133. Caspi, O.; et al. (2007). Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of the American College of Cardiology, 50(19), 1884-1893.
134. Fernandes, S.; et al. (2010). Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. Journal of Molecular and Cellular Cardiology, 49(6), 941-949.
135. van Laake, L. W.; et al. (2009). Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Research, 3(2-3), 106-112.
136. Lu, W. N.; et al. (2009). Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Engineering. Part A, 15(6), 1437-1447.
137. Fujimoto, K. L.; et al. (2009). Naive rat amnion-derived cell transplantation improved left ventricular function and reduced myocardial scar of postinfarcted heart. Cell Transplantation, 18(4), 477-486.
138. Xu, C.; et al. (2006). Cardiac bodies: a novel culture method for enrichment of cardiomyocytes derived from human embryonic stem cells. Stem Cells and Development, 15(5), 631-639.
139. Murry, C. E.; Keller, G. (2008). Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell, 132(4), 661-680.
140. Hattori, F.; et al. (2010). Nongenetic method for purifying stem cell-derived cardiomyocytes. Nature Methods, 7(1), 61-66.
141. Dubois, N. C.; et al. (2011). SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nature Biotechnology, 29(11), 1011-1018.
142. Awasthi, S.; et al. (2012). Label-free identification and characterization of human pluripotent stem cell-derived cardiomyocytes using second harmonic generation (SHG) microscopy. Journal of Biophotonics, 5(1), 57-66.
143. Doevendans, P. A.; et al. (1996). The utility of fluorescent in vivo reporter genes in molecular cardiology. Biochemical and Biophysical Research Communications, 222(2), 352-358.
144. Anderson, D.; et al. (2007). Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Molecular Therapy, 15(11), 2027-2036.
145. Ritner, C.; et al. (2011). An engineered cardiac reporter cell line identifies human embryonic stem cell-derived myocardial precursors. PLoS One, 6(1), e16004.
146. Huber, I.; et al. (2007). Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. The FASEB Journal, 21(10), 2551-2563.
147. Fu, J. D.; et al. (2010). Na+/Ca2+ exchanger is a determinant of excitation-contraction coupling in human embryonic stem cell-derived ventricular cardiomyocytes. Stem Cells and Development, 19(6), 773-782.
148. van Laake, L. W.; et al. (2010). Reporter-based isolation of induced pluripotent stem cell- and embryonic stem cell-derived cardiac progenitors reveals limited gene expression variance. Circulation Research, 107(3), 340-347.
149. Gassanov, N.; et al. (2004). Endothelin induces differentiation of ANP-EGFP expressing embryonic stem cells towards a pacemaker phenotype. The FASEB Journal, 18(14), 1710-1712.
150. Ma, J.; et al. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. American Journal of Physiology - Heart and Circulatory Physiology, 301(5), H2006-H2017.
151. Xu, X. Q.; et al. (2008). Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy, 10(4), 376-389.
152. Recchia, A.; et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proceedings of the National Academy of Sciences of the United States of America, 103(5), 1457-1462.
153. Tsukahara, T.; et al. (2006). Murine leukemia virus vector integration favors promoter regions and regional hot spots in a human T-cell line. Biochemical and Biophysical Research Communications, 345(3), 1099-1107.
154. Woods, N. B.; et al. (2003). Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood, 101(4), 1284-1289.
155. Gropp, M.; Reubinoff, B. (2006). Lentiviral vector-mediated gene delivery into human embryonic stem cells. Methods in Enzymology, 420, 64-81.
156. Nelson, T. J.; et al. (2008). CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells. Stem Cells, 26(6), 1464-1473.
157. Yamashita, J. K.; et al. (2005). Prospective identification of cardiac progenitors by a novel single cell-based cardiomyocyte induction. The FASEB Journal, 19(11), 1534-1536.
158. Hidaka, K.; et al. (2010). The cellular prion protein identifies bipotential cardiomyogenic progenitors. Circulation Research, 106(1), 111-119.
159. Rust, W.; Balakrishnan, T.; Zweigerdt, R. (2009). Cardiomyocyte enrichment from human embryonic stem cell cultures by selection of ALCAM surface expression. Regenerative Medicine, 4(2), 225-237.
160. Van Hoof, D.; et al. (2010). Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. Journal of Proteome Research, 9(3), 1610-1618.
161. Snir, M.; et al. (2003). Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. American Journal of Physiology-Heart and Circulatory Physiology, 285(6), H2355-H2363.
162. Satin, J.; et al. (2004). Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. The Journal of Physiology, 559(Pt 2), 479-496.
163. Dolnikov, K.; et al. (2005). Functional properties of human embryonic stem cell-derived cardiomyocytes. Annals of the New York Academy of Sciences, 1047, 66-75.
164. Sartiani, L.; et al. (2007). Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells, 25(5), 1136-1144.
165. Liu, J.; et al. (2007). Functional sarcoplasmic reticulum for calcium handling of human embryonic stem cell-derived cardiomyocytes: insights for driven maturation. Stem Cells, 25(12), 3038-3044.
166. Binah, O.; et al. (2007). Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes. Journal of Electrocardiology, 40(6 Suppl), S192-S196.
167. Norstrom, A.; et al. (2006). Molecular and pharmacological properties of human embryonic stem cell-derived cardiomyocytes. Experimental Biology and Medicine (Maywood), 231(11), 1753-1762.
168. Otsuji, T. G.; et al. (2010). Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: qualitative effects on electrophysiological responses to drugs. Stem Cell Research, 4(3), 201-213.
169. Brito-Martins, M.; Harding, S. E.; Ali, N. N. (2008). Beta(1)- and beta(2)-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart. British Journal of Pharmacology, 153(4), 751-759.
170. Beqqali, A.; et al. (2006). Genome-wide transcriptional profiling of human embryonic stem cells differentiating to cardiomyocytes. Stem Cells, 24(8), 1956-1967.
171. Kehat, I.; et al. (2004). Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nature Biotechnology, 22(10), 1282-1289.
172. Synnergren, J.; et al. (2008). Cardiomyogenic gene expression profiling of differentiating human embryonic stem cells. Journal of Biotechnology, 134(1-2), 162-170.
173. Kehat, I.; et al. (2002). High-resolution electrophysiological assessment of human embryonic stem cell-derived cardiomyocytes: a novel in vitro model for the study of conduction. Circulation Research, 91(8), 659-661.
174. Rugg-Gunn, P. J.; et al. (2012). Cell-surface proteomics identifies lineage-specific markers of embryo-derived stem cells. Developmental Cell, 22(4), 887-901.
175. Denning, C.; et al. (2006). Common culture conditions for maintenance and cardiomyocyte differentiation of the human embryonic stem cell lines, BG01 and HUES-7. The International Journal of Developmental Biology, 50(1), 27-37.
176. Xu, C.; et al. (2001). Feeder-free growth of undifferentiated human embryonic stem cells. Nature Biotechnology, 19(10), 971-974.
177. Hodgetts, S. I.; et al. (2000). Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplantation, 9(4), 489-502.
178. van Laake, L. W.; et al. (2007). Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Research, 1(1), 9-24.
179. Niebruegge, S.; et al. (2009). Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnology and Bioengineering, 102(2), 493-507.
180. Stevens, K. R.; et al. (2009). Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proceedings of the National Academy of Sciences of the United States of America, 106(39), 16568-16573.
181. Stevens, K. R.; et al. (2009). Scaffold-free human cardiac tissue patch created from embryonic stem cells. Tissue Engineering. Part A, 15(6), 1211-1222.
182. Ye, Z.; et al. (2011). Myocardial regeneration: roles of stem cells and hydrogels. Advanced Drug Delivery Reviews, 63(8), 688-697.
183. Tulloch, N. L.; et al. (2011). Growth of engineered human myocardium with mechanical loading and vascular coculture. Circulation Research, 109(1), 47-59.
184. Caspi, O.; et al. (2007). Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circulation Research, 100(2), 263-272.
185. Gaetani, R.; et al. (2012). Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells. Biomaterials, 33(6), 1782-1790.
186. Nunes, S. S.; et al. (2011). Stem cell-based cardiac tissue engineering. Journal of Cardiovascular Translational Research, 4(5), 592-602.
187. Vrijsen, K. R.; et al. (2010). Cardiomyocyte progenitor cell-derived exosomes stimulate migration of endothelial cells. Journal of Cellular and Molecular Medicine, 14(5), 1064-1070.
188. Lee, Y. K.; et al. (2010). Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway. Molecular Endocrinology, 24(9), 1728-1736.
189. Kim, C.; et al. (2010). Non-cardiomyocytes influence the electrophysiological maturation of human embryonic stem cell-derived cardiomyocytes during differentiation. Stem Cells and Development, 19(6), 783-795.
190. Matsa, E.; Denning, C. (2012). In vitro uses of human pluripotent stem cell-derived cardiomyocytes. Journal of Cardiovascular and Translational Research (in press)